EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Initial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continents

Julien Coussement iD, Shyam B Bansal, Anne Scemla, My H S Svensson, Laura A Barcan, Olivia C Smibert, Wanessa T Clemente, Francisco Lopez-Medrano iD, Tomer Hoffman iD, Umberto Maggiore, Concetta Catalano, Luuk Hilbrands und 14 weitere

Transplant Infectious Disease · 2024-12 · 26 (6)

DOI: 10.1111/tid.14362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, online erschienen am 26.08.2024. Verfasst von Julien Coussement und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Guadeloupe University Hospital, Les Abymes, France. Hauptthemen laut MEDLINE: Pyelonephritis, Kidney Transplantation, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the burden of pyelonephritis after kidney transplantation, there is no consensus on initial empirical antibiotic management.

Methods

We surveyed clinicians throughout the world on their practice and opinions about the initial empirical therapy of post‐transplant pyelonephritis, using clinical vignettes. A panel of experts from 19 countries on six continents designed this survey, and invited 2145 clinicians to participate.

Results

A total of 721 clinicians completed the survey (response rate: 34%). In the hypothetical case of a kidney transplant recipient admitted with pyelonephritis but not requiring intensive care, most respondents reported initiating either a 3rd‐generation cephalosporin (37%) or piperacillin‐tazobactam (21%) monotherapy. Several patient‐level factors dictated the selection of broader‐spectrum antibiotics, including having a recent urine culture showing growth of a resistant organism (85% for extended‐spectrum ß‐lactamase‐producing organisms, 90% for carbapenemase‐producing organisms, and 94% for Pseudomonas aeruginosa ). Respondents attributed high importance to the appropriateness of empirical therapy, which 87% judged important to prevent mortality. Significant practice and opinion variations were observed between and within countries.

Conclusion

High‐quality studies are needed to guide the empirical management of post‐transplant pyelonephritis. In particular, whether prior urine culture results should systematically be reviewed and considered remains to be determined. Studies are also needed to clarify the relationship between the appropriateness of initial empirical therapy and outcomes of post‐transplant pyelonephritis. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyelonephritisKidney TransplantationAnti-Bacterial AgentsHumansSurveys and QuestionnairesTransplant RecipientsFemaleMalePractice Patterns, Physicians'Piperacillin, Tazobactam Drug CombinationAdultMiddle AgedPseudomonas aeruginosaCephalosporinsbeta-Lactamases

Stichwörter der Autor:innen

antimicrobial stewardshipkidney transplantationquestionnaireurinary tract infection

Substanzen

Anti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationCephalosporinsbeta-Lactamases

Autor:innen und Institutionen

  • Department of Infectious Diseases, Guadeloupe University Hospital, Les Abymes, France.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Department of Nephrology, Medanta-Medicity, Gurgaon, India.
  • Department of Kidney Transplantation, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Paris, France.
  • Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark.
  • Internal Medicine Department, Infectious Diseases Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

ORCID-Profile: Julien Coussement, Francisco Lopez-Medrano, Tomer Hoffman, Oriol Manuel, Terence Kee Yi Shern, Ondrej Viklicky, Rainer Oberbauer, Hannah Kaminski, Dafna Yahav, Nassim Kamar, Camille N Kotton

Zitieren

APA

Coussement, J., Bansal, S. B., Scemla, A., Svensson, M. H. S., Barcan, L. A., Smibert, O. C., Clemente, W. T., Lopez-Medrano, F., Hoffman, T., Maggiore, U., Catalano, C., Hilbrands, L., Manuel, O., DU Toit, T., Shern, T. K. Y., Chowdhury, N., Viklicky, O., Oberbauer, R., Markowicz, S., …, & Kotton, C. N. (2024). Initial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continents. Transplant Infectious Disease, 26(6). https://doi.org/10.1111/tid.14362

Vancouver

Coussement J, Bansal SB, Scemla A, Svensson MHS, Barcan LA, Smibert OC, et al. Initial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continents. Transplant Infectious Disease. 2024;26(6). doi:10.1111/tid.14362

BibTeX
@article{Coussement2024,
  author = {Coussement, Julien and Bansal, Shyam B and Scemla, Anne and Svensson, My H S and Barcan, Laura A and Smibert, Olivia C and Clemente, Wanessa T and Lopez-Medrano, Francisco and Hoffman, Tomer and Maggiore, Umberto and Catalano, Concetta and Hilbrands, Luuk and Manuel, Oriol and DU Toit, Tinus and Shern, Terence Kee Yi and Chowdhury, Nizamuddin and Viklicky, Ondrej and Oberbauer, Rainer and Markowicz, Samuel and Kaminski, Hannah and Lafaurie, Matthieu and Pierrotti, Ligia C and Cerqueira, Tiago L and Yahav, Dafna and Kamar, Nassim and Kotton, Camille N},
  title = {Initial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continents},
  journal = {Transplant Infectious Disease},
  year = {2024},
  volume = {26},
  number = {6},
  doi = {10.1111/tid.14362}
}
Kostenlos starten →